Welcome to Animal Health Partnering
Welcome to Animal Health Partnering
Search
Sunshine Act Compliance
Sunshine Act Compliance
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
Board of Managing Directors
Read more about Boehringer Ingelheim's board of managing directors, with information on all five members and their respective responsibilities.
Cooperative Learning Program
CAREER AREAS
Summer Internship Program
CAREER AREAS
Ridgefield Research and Innovation
Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Onboarding
Onboarding
Corporate Strategy & Consulting
Corporate Strategy & Consulting
People, Finance & Organization
People, Finance & Organization
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
Information Technology
IT
Emerging Talent
Early Careers
Borderline Personality Disorder
Borderline Personality Disorder
Get in touch
Get in touch
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Empowering Patients
Empowering Patients
Veterinary Public Health
Veterinary Public Health
Imprint
Here you can access contact details and information about Boehringer Ingelheim
Clinical Studies
Clinical Studies
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
US Privacy Statement
US Privacy Statement
Our Curiosity Never Stops | Boehringer Ingelheim US
Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024